BRAF (R506_K507insVLR)

BRAF · Variant type: indel · HGVS: p.R506_K507insVLR

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Vemurafenib	98.2%	1.8%	96.49
2	Ponatinib	96.6%	3.4%	78.23
3	Dabrafenib	96.2%	3.8%	94.74
4	Encorafenib	95.4%	4.6%	98.50
5	Nilotinib	83.2%	16.8%	96.49
6	Dasatinib	82.9%	17.1%	87.97
7	Ripretinib	73.3%	26.7%	92.95
8	Regorafenib	59.4%	40.6%	95.99
9	Ibrutinib	32.2%	67.8%	94.74
10	Sorafenib	28.4%	71.6%	96.72
11	Bosutinib	19.8%	80.2%	87.22
12	Repotrectinib	18.2%	81.8%	84.21
13	Gedatolisib	16.6%	83.4%	99.75
14	Pazopanib	15.6%	84.4%	97.49
15	Trametinib	14.8%	85.2%	99.50
16	Cobimetinib	14.0%	86.0%	100.00
17	Crizotinib	12.5%	87.5%	91.39
18	Binimetinib	11.2%	88.8%	100.00
19	Brigatinib	10.3%	89.7%	82.96
20	Cabozantinib	9.9%	90.1%	92.73
21	Gefitinib	9.9%	90.1%	99.25
22	Apatinib	9.8%	90.2%	97.73
23	Ceritinib	9.2%	90.8%	95.44
24	Sirolimus	9.0%	91.0%	100.00
25	Pacritinib	8.6%	91.4%	88.64

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Vemurafenib	98.2%	92.8%	+5.4%
Ponatinib	96.6%	99.4%	-2.8%
Dabrafenib	96.2%	98.3%	-2.1%
Encorafenib	95.4%	98.0%	-2.6%
Nilotinib	83.2%	85.8%	-2.6%
Dasatinib	82.9%	80.6%	+2.2%
Ripretinib	73.3%	100.0%	-26.7%
Regorafenib	59.4%	98.3%	-38.9%
Ibrutinib	32.2%	—	—
Sorafenib	28.4%	98.5%	-70.2%
Bosutinib	19.8%	—	—
Repotrectinib	18.2%	—	—
Gedatolisib	16.6%	56.5%	-39.9%
Pazopanib	15.6%	79.3%	-63.8%
Trametinib	14.8%	—	—
Cobimetinib	14.0%	—	—
Crizotinib	12.5%	—	—
Binimetinib	11.2%	—	—
Brigatinib	10.3%	—	—
Cabozantinib	9.9%	—	—
Gefitinib	9.9%	—	—
Apatinib	9.8%	94.1%	-84.4%
Ceritinib	9.2%	—	—
Sirolimus	9.0%	—	—
Pacritinib	8.6%	58.5%	-49.8%

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.7ms